End to End Merged with INC Research to form a fully integrated biopharma solutions organization, enabling cross-sell of clinical and commercial services. This positions the company to address sponsor needs with a single partner across development and launch.

Global Trial Scale The merger created one of the largest CROs, indicating capacity to manage large, complex multinational programs and higher program scope. This supports opportunities to upsell late-stage development, program management, and integrated data capabilities to large sponsors.

Data Driven The organization emphasizes data and insights for global firms, presenting a chance to offer analytics, real-world data strategies, and market access support to sponsors seeking evidence-based decisions.

Public Market History of going public and executing a major merger demonstrates mature governance and integration discipline, reassuring regulated sponsors about outsourcing partnerships and project controls.

Mid-Sized Agility With a mid-market scale, the company can deliver agile, customized teams and faster decision cycles, appealing to biotech and mid-cap sponsors seeking tailored CRO and commercialization support.